mmol/liter; serum cholesterol, 5.95 mmol/liter; serum triglycerides, 1.40 mmol/liter; serum potassium, 4 mmol/liter; serum creatinine, 95 mol/liter (1.1 mg/dl); creatinine clearance, 112 ml/min/1.73 m 2 body surface; and 24-hour urine albumin excretion, 245 mg. Urinalysis revealed no other abnormalities. An electrocardiogram showed a Sokolow-Lyon voltage of 3.9 mV. Doppler ultrasonographic examination of the heart disclosed increased left-ventricular mass index (LVMI ϭ 141 g/m 2 ) and increased left-ventricular relative wall thickness (RWT ϭ 0.47); parameters of diastolic and systolic function were within normal limits. Renal ultrasonography revealed normal-sized kidneys with no parenchymal abnormality. No other medical problems were identified.
CASE PRESENTATIONS
remained about 150/100 mm Hg, and the urinary sodium excrePatient 1. A 42-year-old white man was referred to the Unition ranged between 80 and 100 mmol/day. The lisinopril dose versity Clinic of the University of Navarra for evaluation of was increased to 20 mg daily. Under this therapeutic regimen, arterial hypertension. Three years earlier, the patient had been blood pressure fell to below 140/90 mm Hg during the next told he had elevated blood pressure during an insurance medinine months. One year after the initial medical examination, cal examination. No antihypertensive therapy was prescribed a cardiac echocardiogram revealed diminution of the left-venduring the intervening period. tricular mass index (133 g/m 2 ) and the RWT (0.43), and nepheHis father had had hypertension and had died of a noncarlometric analysis of the urine revealed a 24-hour albumin excrediovascular cause at age 70. The patient had had two episodes tion of 80 mg. of urinary tract infection, but a rapid-sequence pyelogram did Patient 2. A 52-year-old white woman was referred to the not reveal any abnormalities. He suffered often from headUniversity Clinic of the University of Navarra for the evaluaaches, but he had no palpitations, sweating, or orthostatic falls tion of recent-onset hypertension. She had been normotensive in blood pressure. He had no additional cardiovascular risk one year earlier. She had a strong family history of cardiovascufactors: he had never smoked; glucose tolerance was normal; lar disease: Her father died at age 55 with hypertension and and plasma cholesterol concentration was below 6.35 mmol/ a myocardial infarction, and her mother died at age 60 of liter.
hypertension and a cerebrovascular accident. The patient did On presentation at the outpatient clinic, his blood pressure not smoke and drank alcohol only occasionally. was 168/110 mm Hg, and the pulse rate was 74 beats/min and The patient described herself as a healthy, active individual regular. The body mass index was 24 kg/m 2 . Physical examinawithout medical complaints. She had never used oral contration showed evidence of an enlarged left ventricle and a grade ceptives or cardiovascular drugs. Hypercholesterolemia had 2/6 mid-systolic ejection murmur. No carotid or abdominal been detected during a routine medical examination; only dibruits were heard. Pulses in the extremities were normal. No etary treatment had been recommended. edema was present. Neurologic examination was normal. FunPhysical examination revealed a thin, well-developed, wellduscopic examination revealed mild arteriolar narrowing and nourished female. The body mass index was 26 kg/m 2 . The arteriovenous crossing changes. blood pressure was 159/100 mm Hg. Cardiac examination disclosed a normal PMI, and normal sounds were noted. The abdoLaboratory evaluation revealed: fasting plasma glucose, 5.0 men was not remarkable; no abdominal bruit was audible. No edema was evident in the extremities. Musculoskeletal and neurologic examinations were within normal limits. Funduscopy creatinine, uric acid, and electrolytes, were normal, as was
In this Nephrology Forum, I will review the most urinalysis. An electrocardiogram was normal. Ultrasound exprominent data on the biochemistry and biologic actions aminations of the heart and kidneys were unrevealing. Fasting of IGF-I, with a special focus on the physiologic effects plasma insulin concentration was 25 U/ml, above the upper of the factor on the cardiovascular system. Also, I will normal limit for normotensives in our laboratory (20 U/ml). The patient underwent an oral glucose tolerance test after address the evidence suggesting that alterations in the ingestion of a drink containing 40 g glucose/m 2 body surface.
synthesis, secretion, and/or tissue bioavailability of
The two-hour glucose and insulin concentrations were above IGF-I participate in the pathophysiology of essential hythe upper limit of normal in controls (glucose, 7.8 mmol/liter; pertension. Finally, I will propose that some of the beneinsulin, 50 U/ml).
ficial effects produced by ACE inhibitors are related to
The patient began a sodium chloride-and fat-restricted diet, and lisinopril (10 mg once daily) was prescribed. Over the their capacity to modify the production and/or the tissue ensuing six months, her blood pressure was 146/95 mm Hg.
bioavailability of IGF-I in hypertensive patients.
At that time, laboratory examination showed: fasting plasma glucose, 5.50 mmol/liter; serum cholesterol, 6.95 mmol/liter; Biochemistry and physiology of IGF-I serum triglycerides, 1.80 mmol/liter; and fasting plasma insulin, Insulin-like growth factor I belongs to a family of sin-16 U/ml. Pravastatin, a lipid-lowering drug, was begun, and the lisinopril dose was increased to 20 mg once daily. After gle-chain polypeptides (IGF-I and IGF-II) with strucone year of treatment, her blood pressure was below 140/90 tural homology to proinsulin [4] . Insulin-like growth fac- [5] . It comprises at least five Spain): These two patients illustrate some of the most exons spread over more than 90 kbp. The gene encodes relevant pathophysiologic features of essential hypertentwo precursor forms of IGF-I, represented by transcripts sion. The first patient exhibited cardiac and renal damwith distinct 3Ј regions. The resulting precursor forms age, as evidenced by the presence of concentric leftof IGF-Ia and IGF-Ib differ in the terminal portion of ventricular hypertrophy (LVH) and microalbuminuria, their carboxy-terminal peptides. Regulation of IGF-I respectively. The second patient had one of the metagene expression can occur at several sites, namely, gene bolic patterns most frequently found in hypertensives:
transcription, RNA processing and transport, and mRNA impaired glucose tolerance and hyperinsulinemia (durstability, as well as during post-translational events. ing fasting and after a glucose challenge) associated with
The circulating IGF-I is synthesized primarily by the lipid disturbances (increased low-density lipoprotein liver under the control of growth hormone (GH). The cholesterol and triglycerides, and decreased high-density interaction of GH with its hepatic receptor stimulates lipoprotein cholesterol). Interestingly, administration of expression of the IGF-I gene and release of IGF-I pepthe angiotensin-converting enzyme (ACE) inhibitor lisitide [6] . Serum concentrations of IGF-I usually parallel nopril was associated with regression of the left-ventricu-24-hour mean serum concentrations of GH, and IGF-I lar mass and lessening of the microalbuminuria in the inhibits the secretion of GH by the pituitary. Many other first patient and with a decrease of the plasma insulin factors control blood IGF-I concentrations as well levels in the second patient.
( Table 1) . It is now accepted that humoral factors, that is, vasoBesides the liver, many other organs produce IGF-I active substances, hormones, growth factors, and cyto- [7] . Growth hormone, parathyroid hormone, glucocortikines, participate directly in the development of endcoids, and sex steroids regulate the local production of organ damage and metabolic alterations that occur in IGF-I. Sara and Hall have proposed that intact IGF-I, hypertension. Several recent findings have underscored which is bound by IGF-binding proteins (IGFBPs), repthe potential participation of insulin-like growth factor I resents the endocrine form of IGF-I present in the circu-(IGF-I or somatomedin C) in the development of cardiac lation [8] . Truncated IGF-I, which is present in tissues and renal damage in patients with essential hypertension.
and which displays weak affinity of binding to IGFBPs, These findings include the ability of IGF-I to directly represents the locally acting autocrine or paracrine form promote cardiac growth [1] and glomerular alterations [2] and its ability to regulate glucose metabolism [3] .
of IGF-I. According to this model, a protease that trun- Mohan et al recently proposed that IGFBPs also mediate IGF-independent biologic effects [11] . For example, IGFBP-1 stimulates vascular smooth muscle cell (SMC) cates the amino terminus of IGF-I regulates the producmigration in an IGF-independent manner involving tion of endocrine or autocrine-paracrine IGF-I [8] .
binding to integrin receptors [12] . Approximately 99% of the circulating IGF-I is bound
The IGF-I receptor (IGF-IR) is a heterotetrameric to one of six IGFBPs [9] . The six IGFBPs characterized glycoprotein composed of two ligand-binding ␣-subunits to date comprise a structurally related family of secreted of 706 amino acids and two transmembrane ␤-subunits proteins that bind IGF-I with high affinity. The IGFBPs of 627 residues [13] . The human protein is produced by vary in length from 216 to 289 amino acids and are mRNAs derived from a single 21-exon IGF-IR gene composed of shared, cysteine-rich amino-and carboxylocated on chromosome 15q25-q26. The ␣-subunit conterminal domains. In contrast, the central portion of each tains the ligand-binding region of the receptor. The IGFBP is unique. Each of the IGFBPs exhibits its own IGF-IR binds IGF-I with a dissociation constant (Kd) characteristic pattern of expression in different tissues of less than 1 nm in intact cells; IGF-II binds with severaland has a unique pattern of hormonal and developmental fold lower affinity, and insulin with more than 100-fold regulation.
lower affinity [14] . In general, biologic potency parallels The IGFBPs are modulators of IGF-I's action [10] .
binding affinity. The ␤-subunit is composed of a short The IGF-I present in the blood and other biologic fluids extracellular domain, a membrane-spanning segment, is bound to IGFBPs, and this interaction maintains reserand a large intracytoplasmic region containing a tyrosine voirs of this growth factor in the circulation and elsekinase domain and sites of tyrosine and serine phosphorwhere. In conjunction with another circulating protein ylation [14] . termed the acid labile subunit (ALS), IGFBP-3 is primarStimulation of IGF-IR by ligand binding activates the ily responsible for maintaining IGF-I levels in the blood intracellular tyrosine kinase and leads to rapid tyrosine (Fig. 1) . Other IGFBPs found in the bloodstream, includphosphorylation of insulin receptor substrate and to ining IGFBP-1, IGFBP-2, and IGFBP-4, can cross endotracytoplasmic assembly of a complex consisting of a thelial barriers and thus might transport IGF-I from the variety of proteins that are responsible for stimulation circulation to peripheral tissues (Fig. 1) . Several IGFBPs of diverse downstream signal transduction pathways [14] . are found in the extracellular environments of many These events then induce several biologic actions, includtissues and might regulate IGF-I accessibility to receping stimulation of hormone-sensitive glucose transport tors and/or provide a local storage depot. These local [15] and activation of proteins involved in cell growth, functions of IGFBPs could be modulated by interactions differentiation, and survival [16] . with the extracellular matrix and cell surface. In addition, Actions of IGF-I potentially relevant to the local levels of several IGFBPs are modified through spepathophysiology of hypertension cific proteolysis. Thus, the dynamic interactions between IGF-I and its binding proteins regulate the bioavailability The GH/IGF-I axis is primarily involved in the regulation of somatic growth, but it also participates in the and, ultimately, the action of the growth factor. Finally, [35] , vasoactive substances such as angiotensin II [36] , control of a number of physiologic processes, including the regulation of glucose metabolism. Traditionally, inand reactive oxygen species [37] , also induce IGF-I expression in these cells. Thus, IGF-I may be an important terest in the relationship between the GH/IGF-I axis and the cardiovascular system has stemmed from the clinical link in mediating structurally adaptive growth responses in the blood vessel wall. and epidemiologic observations that patients with acromegaly and stimulation of the GH/IGF-I axis have an
In rats, administration of IGF-I decreases blood pressure, a response mediated by nitric oxide (NO) [38] . In increased propensity to develop cardiovascular complications [17] .
vitro experiments have confirmed that NO is an important mediator of IGF-I-induced vascular relaxation [39]. In the past few years, remarkable advancements have been made in our understanding of the cellular and moIn cultured endothelial cells, IGF-I stimulates endothelial NO synthase (eNOS)-mediated NO production [40] . lecular mechanisms involved in IGF-I's action, including its effects on cardiac, vascular, and renal tissues and
In addition, Walsh and colleagues have shown that IGF-I stimulates inducible NO synthase (iNOS)-mediated NO the wide distribution of its receptors in these tissues (Table 2) . Solid evidence now implicates IGF-I in pathoproduction in cultured SMCs [41] . Therefore, IGF-I might play a role in the regulation of blood pressure and physiologic events related to arterial hypertension. Thus, the question is how this interaction is mediated and what regional blood flow via NO. Transgenic mice overexpressing GH also have elespecific role IGF-I plays in relation to other regulators.
Several lines of evidence strongly suggest that IGF-I vated IGF-I levels. In these animals, glomerular enlargement and sclerosis develop as the result of increased participates in the development of cardiac hypertrophy. Insulin-like growth factor I induces hypertrophy of culglomerular production of extracellular matrix proteins [42, 43] . However, mice transgenic for IGF-I also have tured ventricular myocytes [18, 19] . Increased cardiac weight has been observed in mice transgenic for human increased glomerular size but do not develop accelerated glomerular sclerosis, even though serum IGF-I levels in IGF-I with increased circulating levels of the factor [20] . Table 3 . Levels of insulin-like growth factor I (IGF-I) and growth IGF-I transgenic mice also were increased, as in GH hormone (GH) in normotensive control subjects and transgenic animals [42, 43] . This discrepancy is difficult hypertensive patients to explain because glomeruli do not express GH recep- . This hypothesis is supported by the observation that IGF-I stimulates mRNA and secreted protein levels of different extracellular matrix proteins in cultured rat glomerular mesangial cells [44] . IGF-I. Fibroblasts are both a source of IGF-I and a Studies performed in humans [45, 46] and animals [47, target for this growth factor. Insulin-like growth factor I 48] have shown that exogenous and endogenous IGF-I stimulates fibroblast proliferation and increases synthesis raises renal plasma flow and glomerular filtration rate of fibrillar collagen types I and III [59] . Accordingly, (GFR) but produces inconsistent effects on tubular sobiochemical evidence of increased synthesis of fibrillar dium handling [2] . The renal hemodynamic actions of collagen has been found in acromegalic patients with IGF-I seem to be secondary to a reduction in the renal increased circulating levels of IGF-I [60] . Furthermore, efferent, and possibly afferent, arteriolar resistance [48] synthesis of fibrillar collagen returns to normal in acroand might be mediated by local induction and release megalic patients treated with octreotide, a drug that norof NO [49] . In addition, IGF-I administration is accompamalizes IGF-I levels by reducing GH secretion [61] . nied by an increase in the glomerular ultrafiltration coef-A substantial increase in fibrillar collagen has been ficient [48] . Although this effect can be due to the relaxobserved in the cardiac ventricles and the arterial wall ation of the mesangium [50] , the possibility also exists that of animals and humans with arterial hypertension [62, IGF-I increases glomerular capillary permeability [2] . 63]. This fibrosis is the result of both increased collagen Many observations indicate that altered regulation of types I and III synthesis by fibroblasts and unchanged glomerular hemodynamics plays a critical role in the or decreased extracellular collagen degradation [64] . Bepathophysiology of hypertension [51] . Moreover, glosides hemodynamic factors, nonhemodynamic factors, merulosclerosis is one of the most relevant features of that is, growth factors and vasoactive substances, can be clinical hypertension [52] . Thus, IGF-I emerges as a poinvolved in the disequilibrium between collagen synthetential candidate responsible for those renal alterations sis and degradation that occurs in hypertension [65] . in hypertension.
Thus, an excess of IGF-I also might promote the exaggerSeveral studies have demonstrated that IGF-I reduces ated synthesis of fibrillar collagen in hypertensive pablood glucose and serum insulin concentrations in patients as in acromegalic patients. tients with insulin resistance [see Ref. 3 for review]. How IGF-I works in patients with insulin resistance remains Role of IGF-I in human hypertension unclear, but the response to IGF-I in patients with muta-
Quantitative alterations of the GH/IGF-I/IGFBP axis. tions in the insulin-receptor gene or post-receptor defects
Circulating levels of IGF-I are increased in patients with supports the notion that IGF-I acts through mechanisms essential hypertension compared with those in normosimilar to, but distinct from, those of insulin itself, possitensive subjects (Table 3 ) [66, 67] . Although abnormally bly exclusively through the IGF-IR [53, 54] . In addition, high compared to normals, the levels of IGF-I in hyperwhen IGF-I inhibits the secretion and lowers serum and tensives are well below the established lower limit in tissue concentrations of insulin [55] , peripheral tissues patients with active acromegaly [68] . can upregulate their insulin receptors and become more As I said previously, the liver is the major source of responsive to insulin. On the other hand, IGF-I inhibits circulating IGF-I, its hepatic synthesis being under the the secretion of glucagon, normally a powerful stimulus control of GH [6] . Although they were abnormally high to hepatic glucose production [56] .
[66], the GH levels of the hypertensive patients were The existence of glucose intolerance and hyperinsulinwell below values found under conditions of GH hyperemia in almost one-half of the hypertensive population secretion (Table 3) [69]. Several other factors also might has established that resistance to insulin-stimulated gluinfluence circulating IGF-I levels (Table 1) , namely, age, cose uptake is present in these individuals [57, 58] .
estrogen levels, and nutritional status, but no differences Whether stimulation of glucose uptake by IGF-I comin these parameters were found between hypertensives pensates for the defect or defects that block the action with increased IGF-I and normotensives. Nevertheless, of insulin in hypertensives without insulin resistance rethe increased secretion of GH does reflect the loss of mains an interesting possibility.
Extracellular matrix metabolism is also affected by IGF-I-mediated inhibition of feedback in hypertensives. production in these tissues (Table 4 ) [72] . The available data indicate that the observed changes in the IGFBP-1 level in hypertensive patients cannot be attributed either to an excess of cortisol, glucagon, and IGF-I or to a Therefore, the regulation of the GH/IGF-I axis in padeficit of insulin and GH. In fact, although the levels of tients with essential hypertension is abnormal.
IGFBP-1 in serum appear to be related inversely to the We reported that the ratio of IGFBP-3 and IGFBP-1 prevalent insulin levels, the mean levels of insulin were is altered in the serum of patients with essential hypernormal in hypertensive patients with high IGFBP-1 levtension [70] . However, because these binding proteins els. Similarly, glucagon and cortisol levels in these pawere examined by Western ligand blotting, quantitative tients also were within normal limits. In addition, GH interpretation of this qualitative or, at best, semiquantiand IGF-I levels were increased similarly in members of tative method could not be performed. Thus, in a further the two subgroups of hypertensive patients, those with study we analyzed the serum concentrations of these two normal IGFBP-1 levels and those with high IGFBP-1 IGFBPs by specific radioimmunoassay [71] . Whereas the levels. Further studies are necessary to elucidate the concentration of IGFBP-3 was not changed, the concenrole of other potential mechanisms, for example, downtration of IGFBP-1 in hypertensive patients was increased regulation and inhibition of protein kinase C pathway compared with that in normotensive controls. An abnor- [72] , in the increase in serum levels of IGFBP-1 in the mally high concentration of IGFBP-1 was actually obapproximately one-half of patients with essential hyperserved in 53% of hypertensives. The remaining 47% of tension. the hypertensive patients did not exhibit this alteration sive animals and healthy humans [45] [46] [47] [48] . This effect has hypertensive patients might be a factor contributing to been attributed to changes in glomerular hemodynamics hypertension.
mediated by NO. However, Inishi and colleagues reHigh IGF-I levels are associated with LVH in patients ported recently that modulation of glomerular hemodywith essential hypertension [66, 67, 75, 76] . Furthermore, namics by the factor is absent in SHR [82] . This finding compared with hypertensives with normal access to tisaccords with the observation that the ability of IGF-I to sues of IGF-I, hypertensives with increased access to stimulate vascular NO is impaired in essential hypertentissues of the factor exhibited an increased left-ventricusion [73] . Thus, it is unclear whether hyperfiltration oblar mass despite similar levels of blood pressure (Fig. 3) served in hypertensives with increased tissue access of [71] . Therefore, cardiac hypertrophy in these patients circulating IGF-I can result from an increased interaction might result in part from the increased interaction of of the factor with its receptors located in glomerular IGF-I with its cardiac receptors. In support of this possiarterioles. bility is the finding that IGFBP-1 transgenic mice with Several potential mechanisms have been proposed to abnormally high serum concentrations of the protein explain the presence of increased urinary albumin excreproduct had a relative gain in heart weight [77] . tion in patients with essential hypertension. Increased Andronico et al have demonstrated that circulating urinary albumin excretion in hypertension likely is a levels of IGF-I increase in hypertensive subjects followconsequence of increased permeability of the glomerular ing a standard hemodynamic load (that is, standing) profilter, but other factors might be involved, such as the portional to the increase in pressure load, measured as development of glomerular sclerosis [83] . As I previously cardiac rate ϫ blood pressure product [78] . Furthermore, mentioned, IGF-I might enhance glomerular capillary they found a positive correlation between circulating permeability [29] . In addition, IGF-I induces higher IGF-I and the activity of Na ϩ /Li ϩ countertransport in growth response and protein synthesis in mesangial cells patients with essential hypertension [67] . Interestingly, from SHR than in mesangial cells from WKY [84] . Weder and coworkers have shown that Na ϩ /Li ϩ countAn altered IGF-I level can contribute to metabolic ertransport correlates positively with pressure stress on derangements in hypertensive patients. Hypertensives the vascular system [79] . Therefore, one can hypothesize with high IGFBP-1 exhibit lower glucose, triglyceride, that hemodynamic injury of the vascular wall facilitates and insulin levels than do hypertensives with normal the release of local IGF-I into the bloodstream in hyper-IGFBP-1 (Fig. 5) [71]. In addition, compared with hytensive patients. If this is so, the increased circulating pertensives with normal IGFBP-1, patients with high levels of IGF-I in hypertensives could be interpreted IGFBP-1 showed a decreased insulin:glucose ratio and also as a marker of vascular hypertensive damage.
decreased glucagon levels (Fig. 5) [71]. Thus, increased We have reported an association between increased access to tissues of IGF-I could improve glucose metabo-IGF-I levels and altered renal hemodynamics and funclism in essential hypertension, a condition linked to insution in hypertensive patients [80, 81] . We also found that lin resistance [57, 58] . hypertensives with increased tissue access of circulating Our group recently confirmed this possibility [85] . We IGF-I had glomerular hyperfiltration and increased miestimated both insulin resistance and ␤-cell function in croalbuminuria as compared with hypertensives with patients with essential hypertension using the homeostanormal tissue access of the factor (Fig. 4) [71] . sis model assessment [86] . Whereas hypertensives with high IGFBP-1 exhibited normal values of insulin resisAs previously noted, IGF-I raises GFR in normoten-cantly in diabetic patients chronically treated with captopril [94] . The likelihood that ACE inhibitors diminish circulating IGF-I by suppressing the angiotensin IIdependent stimulus for GH production has been confirmed by the finding that GH levels diminish in hypertensive patients chronically treated with ACE inhibitors [75, 76] .
Another aspect of interest is that the response of LVH and extracellular matrix metabolism to ACE inhibitors is related to their ability to normalize IGF-I. In fact, IGF-I levels remained abnormally high after treatment, irrespective of the impact of therapy on blood pressure [75, 76] . Similarly, serum concentrations of PIIIP became normal in hypertensive patients in whom IGF-I levels tance and ␤-cell function, hypertensives with normal IGFBP-1 exhibited abnormally high values of both these decreased to normal values after treatment with lisinopril but remained abnormally high in hypertensives exhibitparameters. Furthermore, we noted an inverse correlation between IGFBP-1 and insulin resistance in the ing increased IGF-I levels after treatment, independently of the response of blood pressure to ACE inhibition [87] . whole group of hypertensives. It therefore appears that increased tissue access of IGF-I counteracts the abnorThese data support the notion that ACE inhibition affects left-ventricular mass and fibrillar collagen metabomal interaction of insulin with its target tissues in essential hypertension.
lism in hypertension through inhibition of the production of circulating IGF-I. We also noted an association between increased serum concentrations of IGF-I and increased serum concentraFinally, we recently observed that long-term administration of lisinopril increases serum levels of IGFBP-1 tions of procollagen type-III amino-terminal peptide (PIIIP) in patients with essential hypertension [87] . Fiand normalizes glucose-related parameters in patients with essential hypertension and insulin resistance at brillar collagen type III is synthesized as a large precursor protein, procollagen type III, which has additional probaseline [85] . Albeit preliminary, these findings reinforce the notion that tissue access of IGF-I might be one of tein sequences (pro-peptides) at its amino-terminal and carboxy-terminal ends. Largely cleaved from the prothe important factors regulating insulin sensitivity in essential hypertension. Further studies are necessary to collagen molecules before these are assembled into fibers, PIIIP then is released into the blood. Serum conconfirm whether the improvement of insulin sensitivity reported in hypertensive patients treated with ACE incentrations of PIIIP therefore could reflect the rate of synthesis of new collagen type III [88] . We believe that hibitors involves changes at the GH/IGF-I/IGFBP axis level. the finding that serum PIIIP is increased in patients with essential hypertension indicates that fibrogenic hyperacConclusion tivity is present in these patients [89] . Thus, the possibility exists that an excess of IGF-I is involved in excess
In this Nephrology Forum, I have updated recent evidence strongly suggesting that alterations in the producorgan and tissue fibrogenesis in patients with essential hypertension.
tion and distribution of circulating IGF-I play a role in some pathophysiologic features of essential hypertension ACE inhibition and the GH/IGF-I/IGFBP axis. We previously demonstrated that the ACE inhibitor capto- (Fig. 6) . The liver overproduces IGF-I and IGFBP-1 under the influence of GH and unknown factors, respecpril, but not the ␤-blocker bisoprolol, decreases circulating IGF-I levels in patients with essential hypertension tively. The hemodynamic loading imposed by hypertension on the vascular wall also might facilitate the local [75]. We later showed that different ACE inhibitors can reduce circulating IGF-I levels irrespective of their synthesis and secretion of IGF-I. However, the lack of response of the endothelium to IGF-I can be responsible chemical structures [76] . Several observations help explain the influence of ACE inhibition on IGF-I levels.
for a lack of vasorelaxant effect of the factor. An excess of circulating IGF-I coupled with an exaggerated access In vitro and in vivo studies suggest that angiotensin II stimulates pituitary GH release both in humans and anito its target tissues can contribute to the development of LVH and an increase in albuminuria. On the other mals [90] [91] [92] . Humans acutely treated with enalapril tend to have diminished GH responses to insulin-induced hyhand, increased tissue availability of IGF-I might stimulate glucose transport by the cells, and this in turn prepoglycemia [93] . Urinary levels of GH decrease signifi- vents pancreatic hypersecretion of insulin and the metaexcretion. On the other hand, an increase in both leftbolic abnormalities linked to insulin resistance. In view ventricular IGF-I mRNA and protein has been described of the complexity of the GH/IGF-I/IGFBP axis, we still in experimental models of high-(two-kidney, one-clip need answers to many questions before we will underGoldblatt hypertension), moderate-(uninephrectomstand the exact role of the axis in the development of ized SHR), and low-renin (DOCA salt rats) hypertenthe end-organ damage and the metabolic disturbances sion [21] [22] [23] . The consistency of the IGF-I findings in associated with hypertension. The potential impact on these three models suggests that they occur indepenthe GH-IGF axis of antihypertensive drugs with welldently of the systemic renin-angiotensin endocrine system. described end-organ protective and metabolically favorNonetheless, a number of in vitro findings suggest that able actions (such as ACE inhibitors) opens an interestangiotensin II interacts with IGF-I at several levels in ing new dimension in the therapy of arterial hypertenSMCs. Exposure of SMCs to angiotensin II markedly sion. No doubt, information on this topic will increase increases IGF-I mRNA [36] . Angiotensin II stimulates in the near future, and a better understanding of the IGF-IR gene transcription by a protein kinase C-indeprecise role of IGF-I in hypertension will enhance our pendent pathway [95] . Furthermore, angiotensin II inability to assess and treat hypertensive patients.
duces rapid tyrosine phosphorylation of IGF-IR substrate-1 [96] . Interestingly, the angiotensin II-induced increase in DNA synthesis is almost completely abol-QUESTIONS AND ANSWERS ished when SMCs are coincubated with an anti-IGF-I Dr. Nicolaos E. Madias (Chief, Division of Nephrolantibody [36] . Angiotensin II thus stimulates transcripogy, New England Medical Center, Boston, Massachution of the IGF-I and IGF-IR genes in SMC, and the setts, USA): In addition to a subpopulation of patients interaction of IGF-I with its receptor is required for with essential hypertension, do patients with secondary angiotensin II-induced DNA synthesis in these cells. This hypertension also manifest elevated serum IGF-I levels?
interaction might have particular relevance to our underDoes the level of plasma renin activity influence the level standing of the synergistic action of angiotensin II and of IGF-I whether in experimental or clinical hyperten-IGF-I for promoting SMC proliferation in vivo [97] . sion?
Dr. Madias: How strong is the evidence that the serum Dr. Díez: Acromegalic patients with hypertension IGFBP-1 determines the tissue accessibility of the facalso exhibit increased serum levels of IGF-I [17] . No tor? After all, altered concentrations of the IGFBPs data are available regarding serum levels of IGF-I in might not necessarily imply altered distribution of IGF-I patients with other forms of secondary hypertension. among them. Do you have information about the saturaWith respect to your second question, there are no clinition of these IGFBPs and their affinity for IGF-I in cal data on serum levels of IGF-I in hypertensive patients normotension versus hypertension? classified according to the level of plasma renin activity as it relates to the concurrent rate of urinary sodium Dr. Díez: Several potential mechanisms for enhancing IGF-I bioavailability in the target tissues have been provolved in the increased sensitivity of SHR mesangial cells to the growth-promoting effect of IGF-I, that same posed [98] : increase of the level of free IGF-I, increase of the ratio of IGF-I to IGFBP-3, increase of the ratio mechanism may be involved in the pathogenesis of the glomerular alterations seen in hypertension, that is, gloof IGFBP-1 to IGFBP-3, increase of the rate of proteolysis of IGFBP-3, decrease of the rate of proteolysis of merulosclerosis. Dr. Madias: Just as is the case for IGF-I, about 50% of IGFBP-1, and increase of IGF-IR abundance in the target tissues. Data presented today in hypertensive papatients with essential hypertension have an overactive Na ϩ /H ϩ exchanger in their blood cells. This phenotype tients are in agreement with the first three possibilities. Thus, it is reasonable to hypothesize that increased seis associated with a number of adverse cardiorenal manifestations. What do we know about the relationship berum levels of IGFBP-1 determine increased transport of circulating IGF-I to its target cells in hypertensive patween IGF-I and the Na ϩ /H ϩ exchanger? Do patients with high access to tissues of IGF-I also have an overactients with increased serum levels of IGF-I and normal serum levels of IGFBP-3. Although we have not anative Na ϩ /H ϩ exchanger? Do mice transgenic for IGF-I overexpress the Na ϩ /H ϩ exchanger? lyzed changes in the saturation level or in the affinity of IGFBPs for IGF-I, about 75% of IGF-I in the circulation Dr. Díez: Recently, Andronico et al reported a positive correlation between circulating IGF-I and the activis complexed with IGFBP-3, whereas almost all the remainder of the circulating IGF-I is bound to lower molecity of erythrocyte Na ϩ /Li ϩ countertransport in patients with essential hypertension [67] . Hypertensives with inular-mass IGFBPs, namely IGFBP-1 [9] . On the other hand, IGFBP-3 has a higher affinity for IGF-I than does creased Na ϩ /Li ϩ countertransport activity have a worse cardiovascular risk profile than do hypertensive patients IGFBP-1 (2.1 and 6.5 nm, respectively) [99] . Thus, an excess of IGFBP-1 might not be enough to modify the with normal Na ϩ /Li ϩ countertransport [104] . Canessa has proposed that Na ϩ /Li ϩ countertransport represents distribution of bound IGF-I in such a way that changes in the tissue access of the factor result. However, findings a mode of functioning of the cell membrane Na therefore could reflect an overactive Na ϩ /H ϩ exchanger. On the other hand, recent papers reported that IGF-I IGF-I to its target tissues parallels changes in the ratio between serum IGFBP-1 and serum IGFBP-3, irrespecstimulates Na ϩ /H ϩ exchanger activity in SMCs [106, 107] . Since IGF-IR are present in erythrocytes, it is tive of changes in the saturation and affinity of these IGFBPs [100] .
tempting to speculate that an excess of IGF-I results in overactivity of the erythrocyte Na Dr. Díez: Increased sensitivity to the growth-promotMadrid): Your findings indicate that IGFBP-1 is involved in insulin resistance in patients with essential hypertening effects of specific growth factors, including IGF-I, has been shown in SMCs from hypertensive animals [101] .
sion. Do data support a glucoregulatory role for this protein? Upregulation of IGF-IR is accompanied by increased responsiveness of SMCs to IGF-I [102] . Interestingly, Dr. Díez: Possible evidence of the glucoregulatory role of IGFBP-1 is seen in fasting healthy subjects followseveral growth factors and angiotensin II increase IGF-IR in SMCs [102] . Together, these findings suggest that ing a single injection of recombinant human IGF-I, which elicits a profound acute increase in serum IGFBP-1 levhypersensitivity to IGF-I mediates SMC hypertrophic and hyperplastic responses to growth factors in arterial els, accompanied by a marked suppression of insulin levels and a 20% decline in blood glucose [108] . The peak hypertension. On the other hand, Heidenreich et al have shown that IGF-I induces higher growth response in IGFBP-1 response at six hours is strongly associated with the peak glucose response at eight hours. Thus mesangial cells from SHR than in mesangial cells from WKY rats [84] . These authors also demonstrated that the insulin-like activity of IGF-I, in conditions in which insulin secretion is greatly suppressed, might be closely changes of cytosolic free-calcium concentration were not associated with increased responsiveness of SHR mesanregulated by IGFBP-1 [108] . Dr. Rodicio: You found that serum levels of IGFBP-1 gial cells to IGF-I [84] . In this regard, it is possible that the tyrosine kinase activity of growth factors is crucial are inversely related to insulin resistance in patients with essential hypertension. Do you know other clinical confor mesangial cell mitogenicity rather than effects on cytoplasmic calcium [103] . Whatever the mechanism inditions in which a similar association has been found? Dr. Díez: Polycystic ovary syndrome also is charactereNOS-mediated NO production by endothelial cells. Could you elaborate on the molecular mechanisms inized by insulin resistance. Morris and Falcone found that serum IGFBP-1 concentrations related positively to volved in such an effect? Can IGF-I also regulate the inducible form of NOS? insulin sensitivity (r ϭ 0.76, P Ͻ 0.003, N ϭ 15) in this condition [109] . Furthermore, IGFBP-1 concentration Dr. Díez: In fact, stimulation with IGF resulted in a rapid, dose-dependent increase in NO in cultured human remained a significant predictor of insulin sensitivity when controlled for the body mass index in these women.
umbilical NO production by both types of endothelial cells is mediated via a tyrosine kinase-dependent mechanism. DisStudies carried out by Ding and associates strongly suggest that the IGF-I resistance in chronic renal failure is crepant data have been reported concerning the potential effects of IGF-I on the inducible form of NOS. Schini caused, at least in part, by an IGF-I post-receptor defect [111] . However, Mak recently reported that the ability et al found that IGF-I inhibits cytokine-mediated induction of NOS expression and activity in SMCs [114] . In of IGF-I infusion to stimulate total-body glucose uptake is maintained in rats with chronic renal failure that are contrast, Walsh et al reported that IGF-I stimulates inducible NOS-mediated NO production in SMCs [115] . insulin resistant [112] . It is therefore unclear how changes in tissue accessibility and actions of IGF-I participate in Since methods used in the two studies were different, further studies are necessary to clarify the real impact the multifactorial origin of insulin resistance in chronic renal failure.
of IGF-I on inducible NOS. Dr. Egido: A number of in vitro studies have shown Dr. Egido: From your findings, it appears that treatment with an ACE inhibitor increases the serum level of that IGF-I inhibits apoptosis. Have you any information on the ability of IGF-I to block apoptosis in vivo? IGFBP-1. Do you have any information on the potential ability of angiotensin II to regulate IGFBP synthesis? Dr. Díez: Resnicoff and colleagues showed that IGF-I protects cells from apoptosis in transplanted tumors Dr. Díez: In fact, we recently observed that chronic administration of the ACE inhibitor lisinopril is as- [116] . Moreover, its administration attenuates cardiomyocyte death in ischemic reperfusion injury [26] . A recent sociated with a significant increase in serum levels of IGFBP-1 in patients with essential hypertension [85] .
report showed that overexpression of human IGF-I in transgenic mice protects from cardiomyocyte apoptosis This effect appears to be independent of the hemodynamic effect of the drug. Thus, the increase might be after infarction [117] . The mechanisms by which IGF-I prevents apoptosis are unknown, but the IGF-I/IGF-IR related to the ACE inhibition. Whereas angiotensin II infusion reduces serum IGFBP-3 levels and increases system mediates the formation of some molecules that inhibit apoptosis (that is, Bcl-2 oncoproteins) [27] . In serum IGFBP-2 levels in rats, no changes have been observed in the serum levels of other IGFBPs, including addition, IGF-I blocks the activation of some members of the interleukin-converting-enzyme family that act as IGFBP-1 [113] . The possibility therefore exists that changes in serum IGFBP-1 levels after lisinopril treatan effector of apoptosis [118] . Dr. Rodicio: Would you comment on the effects of ment are unrelated to a reduced availability of angiotensin II but relate to changes in other active fragments of IGF-I on sodium homeostasis and tubular sodium handling? angiotensin II-that is, angiotensin II (1-7), angiotensin III, angiotensin IV-or increased availability of bradyki- [119] . Such activation could account for increased distal tubular sodium and fluid absorption. In have data on the existence of an alteration in the negative feedback of IGF-I on GH secretion? our study, no differences in either net or fractional sodium excretion were observed between hypertensive paDr. Díez: As I said, the association of increased GH levels with exaggerated IGF-I levels in patients with estients with increased tissue access of circulating IGF-I and hypertensive patients with normal tissue access of sential hypertension suggests loss of the physiologic suppression of GH secretion by IGF-I [69]. Advancing age circulating IGF-I [71]. It is important to note that all these patients were studied under conditions of lowis associated with an apparent reduction in sensitivity to the GH-suppressive effects of IGF-I [122] . However, no moderate sodium intake (100-120 mmol/day).
Dr. Pietro Zucchelli (Professor, Malpighi Departdifferences in age were observed among hypertensive patients with increased levels of GH, hypertensives with ment of Nephrology, Policlinico S. Orsola-Malpighi, Bologna, Italy): Could increased delivery of circulating normal levels of the hormone, and normotensive individuals [69] . Studies looking at the GH-suppressive effect IGF-I to the tubulointerstitial space be involved in the development of chronic renal disease in essential hyperof recombinant human IGF-I infusion could be useful to determine the sensitivity of GH secretion to IGF-I tension?
Dr. Díez: Mice transgenic for the human IGF-I gene negative feedback in hypertensive patients. Dr. Ricardo Bosch (Professor, Department of Physidisplay renal hypertrophy without sclerosis [42, 43] . In contrast, excess of GH and IGF-I, as in transgenic mice ology, University of Alcalá de Henares, School of Medicine, Alcalá de Henares, Spain): Are you aware of studies expressing the bovine GH gene [42, 43] , favors the development of renal sclerosis. Both GH and IGF-I may act looking at the urinary excretion of IGF-I in patients with essential hypertension? synergistically for the development of experimental nephrosclerosis. This is consistent with in vitro observaDr. Díez: To my knowledge, no studies have investigated urinary levels of IGF-I in patients with essential tions of a synergistic effect of these peptides on fibroblast proliferation [120] . Interestingly, hypertensive patients hypertension. However, a recent report described significantly increased urinary IGF-I levels in patients with with increased tissue access of circulating IGF-I also nondiabetic renal disease and chronic renal failure as exhibited elevated levels of GH [71] . Certainly, we can compared to levels in patients with nondiabetic chronic speculate that the interaction of GH and IGF-I facilitates renal disease and normal renal function and in healthy the development of tubulointerstitial fibrosis in these controls [123] . Urinary IGF-I did not correlate with sepatients.
rum IGF-I but demonstrated a significant negative correDr. José M. Lopez-Novoa (Professor and Chairman, lation with the clearance of creatinine in nondiabetic Department of Physiology, University of Salamanca, patients [123] . These data in nondiabetic patients with School of Medicine, Salamanca, Spain): You have shown renal disease suggest the possible participation of renal that IGF-I infusion in humans and animals is associated IGF-I in the progression of renal disease as a potential with an increase in GFR. However, this parameter was "toxic" protein for tubular cells. only slightly increased in hypertensive patients with inDr. Madias: Are there observations either in animals creased tissue accessibility of the factor as compared or humans on the effects of octreotide on the cardiovaswith hypertensive patients who had normal tissue accescular system and the kidneys? sibility. How do you explain these findings? Dr. Díez: Yes, increasing evidence supports a potenDr. Díez: Kurokawa's group recently reported that tial therapeutic role for the somatostatin analogue oc-IGF-I infusion, which increases GFR in normotensive treotide in several cardiovascular and renal pathologic WKY rats, fails to induce the same effect in SHR [82] .
conditions. For instance, suppression of GH production The mechanism underlying this discrepant renal reby octreotide in patients with acromegaly is associated sponse is not known. It is possible that the ability of with a significant regression of LVH and improvement IGF-I to induce NO-mediated renal vasodilation and of cardiac function [17] . On the other hand, octreotide increase GFR is impaired in hypertension [73] . On the infusion into either patients with essential hypertension other hand, IGF-I-induced attenuation of mesangial cell [124] or hypertensive patients with type-II diabetes [125] contraction by vasoactive agents is diminished in cells is accompanied by a significant decrease in plasma insulin from SHR as compared to cells from normotensive WKY levels and an increased natriuretic response to a sodium rats [121] . Therefore, renal SMCs and glomerular cells load. Finally, in rats with streptozotocin-induced diabefrom hypertensive rats appear to be resistant to the relaxtes, octreotide can prevent the development of structural ant effects of IGF-I. Whether this is also the case in and functional renal damage [126] . patients with essential hypertension and increased tissue access of circulating IGF-I deserves further studies. 
